RARE ULTRAGENYX PHARMACEUTICAL INC US FDA Inspections 8-K Filing 2024 - FDA Meeting for UX111 Gene Therapy Ultragenyx Pharmaceutical announced a successful meeting with the FDA regarding the submission of a biologics license application for UX111 gene therapy for Sanfilippo syndrome.Get access to all SEC 8-K filings of the ULTRAGENYX PHARMACEUTICAL INC